Orap in pregnancy
The summary of product characteristics for Orap (pimozide; Janssen) now states that the drug should not be administered to women of childbearing potential, particularly during the first trimester of pregnancy, unless, in the opinion of the physician, the expected benefits of the drug to the patient outweigh the potential risk to the foetus.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067430
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com